Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.

Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, Mwita W, Suriyanon V, Rangsin R, Nelson KE, Sonnenberg P, Fitzgerald D, Karita E, Zaba B.

AIDS. 2007 Nov;21 Suppl 6:S55-63. doi: 10.1097/01.aids.0000299411.75269.e8.

PMID:
18032940
2.

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.

eligibility for ART in lower income countries (eART-linc) collaboration., Wandel S, Egger M, Rangsin R, Nelson KE, Costello C, Lewden C, Lutalo T, Ndyanabo A, Todd J, Van der Paal L, Minga A, Zwahlen M.

Sex Transm Infect. 2008 Aug;84 Suppl 1:i31-i36. doi: 10.1136/sti.2008.029793.

3.

HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda.

Van der Paal L, Shafer LA, Todd J, Mayanja BN, Whitworth JA, Grosskurth H.

AIDS. 2007 Nov;21 Suppl 6:S21-9.

PMID:
18032935
4.

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP.

JAMA. 1998 Nov 4;280(17):1497-503.

PMID:
9809730
5.

The natural history of HIV-1 infection in young Thai men after seroconversion.

Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, Robb M, Beyrer C, Ruangyuttikarn C, Markowitz LE, Nelson KE.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):622-9.

PMID:
15097306
7.

HIV-infected Rwandan women have a high frequency of long-term survival.

Peters PJ, Karita E, Kayitenkore K, Meinzen-Derr J, Kim DJ, Tichacek A, Allen SA.

AIDS. 2007 Nov;21 Suppl 6:S31-7. doi: 10.1097/01.aids.0000299408.52399.e1.

PMID:
18032936
8.

Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up.

Glynn JR, Sonnenberg P, Nelson G, Bester A, Shearer S, Murray J.

AIDS. 2007 Mar 12;21(5):625-32.

PMID:
17314525
9.

Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P.

Int J Epidemiol. 1998 Apr;27(2):289-95.

PMID:
9602412
10.

Survival following HIV infection of a cohort followed up from seroconversion in the UK.

Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K; UK Register of HIV Seroconverters..

AIDS. 2008 Jan 2;22(1):89-95.

PMID:
18090396
11.

Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda.

Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, Kiwanuka N, Nalugoda F, Kigozi G, Ndyanabo A, Bwanika JB, Reynolds SJ, Quinn T, Opendi P.

AIDS. 2007 Nov;21 Suppl 6:S15-9. doi: 10.1097/01.aids.0000299406.44775.de.

PMID:
18032934
12.

Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration..

JAMA. 2008 Jul 2;300(1):51-9. doi: 10.1001/jama.300.1.51.

PMID:
18594040
13.

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group..

PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

14.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study..

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
15.

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, Hernàndez-Aguado I; GEMES (Spanish Multicenter Study Group of Seroconverters)..

AIDS. 2003 Feb 14;17(3):353-9.

PMID:
12556689
16.

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.

Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G.

AIDS. 1997 Mar 15;11(4):461-7.

PMID:
9084793
17.

The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up.

Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE.

AIDS. 2007 Nov;21 Suppl 6:S39-46. doi: 10.1097/01.aids.0000299409.29528.23.

PMID:
18032937
18.

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K; CASCADE Collaboration..

Ann Neurol. 2008 Feb;63(2):213-21.

PMID:
17894380
19.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration..

HIV Med. 2000 Oct;1(4):224-31.

20.

Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil.

Djomand G, Duerr A, Faulhaber JC, Struchiner CJ, Pacheco AG, Barroso PF, Melo MF, Schechter M.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):401-4.

PMID:
17031316

Supplemental Content

Support Center